Background The aim of this study was to evaluate the short-and long-term safety experience
of infliximab treatment in patients with Crohn's disease (CD) in clinical practice. Methods The …

Background & Aims: The aim of this study was to evaluate the short-and long-term safety of
infliximab in patients with Crohn's disease in clinical practice. Methods: The medical records …

Background The aim of this study was to assess the long-term usage patterns and safety of
infliximab in patients with Crohn's disease in clinical practice. Methods The medical records …

OBJECTIVE: The aim of this study was to report the clinical outcome and adverse events in
the first 100 patients with refractory inflammatory and/or fistulizing Crohn's disease treated …

OBJECTIVE: To determine whether the clinical efficacy and safety of infliximab in diverse
clinical referral practices was similar to that seen in the randomized, controlled clinical trials …

BACKGROUND: Efficacy of infliximab in Crohn's disease (CD) showed by randomized
controlled trials must be confirmed in clinical practice. We aimed to evaluate efficacy and …

OBJECTIVES: To evaluate prescription practices and response to infliximab treatment for
Crohn's disease (CD). PATIENTS AND METHODS: The files of CD patients treated with at …

Background The purpose of this study was to compare the long-term safety of infliximab and
nonbiologic agents as Crohn's disease (CD) therapy. Methods Patients with CD were …

Background Infliximab is recognized as an effective therapy in unresponsive luminal and
fistulating Crohn's disease. The use of maintenance or 'on demand'therapy thereafter is …

AIM: To report the clinical outcome and side effects of the first 100 patients with refractory
inflammatory and/or fistulizing Crohn's disease (CD) treated with infliximab, at the Mayo …